MIRA INFORM REPORT

 

 

Report Date :

10.09.2013

 

IDENTIFICATION DETAILS

 

Name :

DAITO PHARMACEUTICAL CO.,LTD.

 

 

Registered Office :

326, Yoka-machi, Toyama-Shi, 939-8567

 

 

Country :

Japan

 

 

Financials (as on) :

31.05.2013

 

 

Date of Incorporation :

March, 2010

 

 

Legal Form :

Public Parent

 

 

Line of Business :

Subject is engaged in the active pharmaceutical ingredient (API) and formulation business.

 

 

No. of Employees :

560

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March, 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Japan

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

japan - ECONOMIC OVERVIEW

 

In the years following World War II, government-industry cooperation, a strong work ethic, mastery of high technology, and a comparatively small defense allocation (1% of GDP) helped Japan develop a technologically advanced economy. Two notable characteristics of the post-war economy were the close interlocking structures of manufacturers, suppliers, and distributors, known as keiretsu, and the guarantee of lifetime employment for a substantial portion of the urban labor force. Both features are now eroding under the dual pressures of global competition and domestic demographic change. Japan's industrial sector is heavily dependent on imported raw materials and fuels. A small agricultural sector is highly subsidized and protected, with crop yields among the highest in the world. While self-sufficient in rice production, Japan imports about 60% of its food on a caloric basis. For three decades, overall real economic growth had been spectacular - a 10% average in the 1960s, a 5% average in the 1970s, and a 4% average in the 1980s. Growth slowed markedly in the 1990s, averaging just 1.7%, largely because of the after effects of inefficient investment and an asset price bubble in the late 1980s that required a protracted period of time for firms to reduce excess debt, capital, and labor. Modest economic growth continued after 2000, but the economy has fallen into recession three times since 2008. A sharp downturn in business investment and global demand for Japan's exports in late 2008 pushed Japan into recession. Government stimulus spending helped the economy recover in late 2009 and 2010, but the economy contracted again in 2011 as the massive 9.0 magnitude earthquake and the ensuing tsunami in March disrupted manufacturing. The economy has largely recovered in the two years since the disaster, but reconstruction in the Tohoku region has been uneven. Newly-elected Prime Minister Shinzo ABE has declared the economy his government's top priority; he has pledged to reconsider his predecessor's plan to permanently close nuclear power plants and is pursuing an economic revitalization agenda of fiscal stimulus and regulatory reform and has said he will press the Bank of Japan to loosen monetary policy. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, Japan in 2012 stood as the fourth-largest economy in the world after second-place China, which surpassed Japan in 2001, and third-place India, which edged out Japan in 2012. The new government will continue a longstanding debate on restructuring the economy and reining in Japan's huge government debt, which exceeds 200% of GDP. Persistent deflation, reliance on exports to drive growth, and an aging and shrinking population are other major long-term challenges for the economy.

 

Source : CIA

 


Company name and address

 

DAITO PHARMACEUTICAL CO.,LTD.    

           

 

326, Yoka-machi

Toyama-Shi, 939-8567

Japan

 

Tel:

81-76-4215665

Fax:

81-76-4216006

www.daitonet.co.jp

 

Employees:

560

Company Type:

Public Parent

Corporate Family:

2 Companies

Traded:

Tokyo Stock Exchange:

4577

Incorporation Date:

Mar-2010

Auditor:

KPMG AZSA LLC

Financials in:

USD (In Millions)

Fiscal Year End:

31-May-2013

Reporting Currency:

Japanese Yen

Annual Sales:

336.4  1

Net Income:

20.8

Total Assets:

344.6  2

Market Value:

142.6

 

(23-Aug-2013)

    

 

Business Description

      

 

Daito Pharmaceutical Co., Ltd. is a Japan-based company mainly engaged in the active pharmaceutical ingredient (API) and formulation business. The Company is engaged in the manufacture, purchase, sale and entrusted manufacture business of active pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation for prescription pharmaceuticals and general pharmaceuticals. In addition, the Company is also engaged in the sale of health food and pharmaceutical related products including quasi drug. As of May 31, 2012, the Company had two consolidated subsidiaries in Japan and the United States. For the fiscal year ended 31 May 2013, Daito Pharmaceutical Co.,Ltd. revenues increased 7% to Y28.96B. Net income applicable to common stockholders increased 29% to Y1.79B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from NOP Interest expenses decrease of 20% to Y126.3M (expense), NOP Other non-operating expenses decrease of 36% to Y27.1M (expense).

 

Industry            

 

Industry

Pharmaceutical Manufacturing

ANZSIC 2006:

1841 - Human Pharmaceutical and Medicinal Product Manufacturing

ISIC Rev 4:

2100 - Manufacture of pharmaceuticals, medicinal chemical and botanical products

NACE Rev 2:

2110 - Manufacture of basic pharmaceutical products

NAICS 2012:

325411 - Medicinal and Botanical Manufacturing

UK SIC 2007:

2110 - Manufacture of basic pharmaceutical products

US SIC 1987:

2833 - Medicinal Chemicals and Botanical Products

 

 

 

Key Executives     

   

Name

Title

Yasunobu Ohtsuga

President, Representative Director

Hisao Abe

Executive Officer, Director of Finance, Deputy Chief Director of Administration

Mitsuo Hirono

Executive Officer, Director of Human Resources and General Affairs, Chief Director of Administration

Masuo Nomura

Executive Officer, Manager of Business Planning Office

Shinjiro Sasayama

Director

 

 

                                          

Significant Developments 

 

Topic

#*

Most Recent Headline

Date

Officer Changes

1

Daito Pharmaceutical Co Ltd Appoints New Chairman of the Board

15-Mar-2013

Equity Financing / Related

2

Daito Pharmaceutical Co Ltd Announces Amount of Shares Issued through Private Placement

15-Mar-2013

Dividends

1

Daito Pharmaceutical Co Ltd to Issue Year-end Dividend for FY 2013

9-Jul-2013

 

 

* number of significant developments within the last 12 months

 

 

News

 

Title

Date

Daito Pharmaceutical Co FY Grp Net Pft Y1.79B Vs Y1.39B Pft Yr Earlier
Nikkei English News (80 Words)

9-Jul-2013

Daito Pharmaceutical Co 9Mos Grp Net Pft Y1.13B Vs Y1.09B Pft Yr Earlier
Nikkei English News (79 Words)

9-Apr-2013

Daito Pharmaceutical Co Ltd Appoints New Chairman of the Board
Reuters UK (29 Words)

15-Mar-2013

 

 

 

Financial Summary

 

As of 31-May-2013

Key Ratios

Company

Industry

Current Ratio (MRQ)

1.36

2.09

Quick Ratio (MRQ)

1.07

1.48

Debt to Equity (MRQ)

0.85

0.43

Sales 5 Year Growth

6.89

4.13

Net Profit Margin (TTM) %

6.17

17.06

Return on Assets (TTM) %

5.52

9.59

Return on Equity (TTM) %

13.60

18.98

Stock Snapshot

   

 

Traded: Tokyo Stock Exchange: 4577

 

As of 23-Aug-2013

   Financials in: JPY

Recent Price

1,421.00

 

EPS

189.24

52 Week High

1,645.00

 

Price/Sales

0.49

52 Week Low

1,118.00

 

Dividend Rate

30.00

Avg. Volume (mil)

0.02

 

Price/Earnings

6.86

Market Value (mil)

14,047.96

 

Price/Book

0.95

 

 

 

Beta

0.68

 

Price % Change

Rel S&P 500%

4 Week

0.14%

2.37%

13 Week

-1.18%

3.36%

52 Week

24.43%

-16.66%

Year to Date

5.57%

-20.49%

 

1 - Profit & Loss Item Exchange Rate: USD 1 = JPY 86.08083
2 - Balance Sheet Item Exchange Rate: USD 1 = JPY 100.8861

 

 

Corporate Overview

 

Location
326, Yoka-machi
Toyama-Shi, 939-8567
Japan

 

Tel:

81-76-4215665

Fax:

81-76-4216006

 

www.daitonet.co.jp

Quote Symbol - Exchange

4577 - Tokyo Stock Exchange

Sales JPY(mil):

28,956.3

Assets JPY(mil):

34,762.3

Employees:

560

Fiscal Year End:

31-May-2013

 

Industry:

Biotechnology and Drugs

Incorporation Date:

Mar-2010

Company Type:

Public Parent

Quoted Status:

Quoted

 

President, Representative Director:

Yasunobu Ohtsuga

 

 

 

 

 

 

 

 

 

 

 

 

Industry Codes

 

ANZSIC 2006 Codes:

1841

-

Human Pharmaceutical and Medicinal Product Manufacturing

4129

-

Other Specialised Food Retailing

 

ISIC Rev 4 Codes:

2100

-

Manufacture of pharmaceuticals, medicinal chemical and botanical products

4721

-

Retail sale of food in specialized stores

 

NACE Rev 2 Codes:

2110

-

Manufacture of basic pharmaceutical products

2120

-

Manufacture of pharmaceutical preparations

4729

-

Other retail sale of food in specialised stores

 

NAICS 2012 Codes:

325411

-

Medicinal and Botanical Manufacturing

325412

-

Pharmaceutical Preparation Manufacturing

445299

-

All Other Specialty Food Stores

 

US SIC 1987:

2833

-

Medicinal Chemicals and Botanical Products

2834

-

Pharmaceutical Preparations

5499

-

Miscellaneous Food Stores

 

UK SIC 2007:

2110

-

Manufacture of basic pharmaceutical products

4729

-

Other retail sale of food in specialised stores

2120

-

Manufacture of pharmaceutical preparations

 

 

Business Description

 

Daito Pharmaceutical Co., Ltd. is a Japan-based company mainly engaged in the active pharmaceutical ingredient (API) and formulation business. The Company is engaged in the manufacture, purchase, sale and entrusted manufacture business of active pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation for prescription pharmaceuticals and general pharmaceuticals. In addition, the Company is also engaged in the sale of health food and pharmaceutical related products including quasi drug. As of May 31, 2012, the Company had two consolidated subsidiaries in Japan and the United States. For the fiscal year ended 31 May 2013, Daito Pharmaceutical Co.,Ltd. revenues increased 7% to Y28.96B. Net income applicable to common stockholders increased 29% to Y1.79B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from NOP Interest expenses decrease of 20% to Y126.3M (expense), NOP Other non-operating expenses decrease of 36% to Y27.1M (expense).

 

 

More Business Descriptions

Manufacture and sale of pharmaceutical products

Pharmaceutical Mfr

 

 

Financial Data

 

Financials in:

JPY(mil)

 

Revenue:

28,956.3

Net Income:

1,786.6

Assets:

34,762.3

Long Term Debt:

5,346.3

 

Total Liabilities:

20,011.9

 

Working Capital:

-2.0

 

 

 

Date of Financial Data:

31-May-2013

 

1 Year Growth

6.6%

28.6%

16.2%

 

 

Market Data

 

Quote Symbol:

4577

Exchange:

Tokyo Stock Exchange

Currency:

JPY

Stock Price:

1,421.0

Stock Price Date:

08-23-2013

52 Week Price Change %:

24.4

Market Value (mil):

14,047,960.0

 

SEDOL:

B6293R4

ISIN:

JP3486150000

 

Equity and Dept Distribution:

03/24/2010, anticipated IPO 2,070,000 shares @ Y1,370 per share by Daiwa Securities Capital Markets Co., Ltd.

 

 

Shareholders

 

 

Major Shareholders

Japan Trustee Services (5.3%); Shinjiro Sasayama (5.1%)

 

 

Key Corporate Relationships

Auditor:

KPMG AZSA LLC

 

Auditor:

KPMG AZSA LLC

 

 

 

 

 

 

 

 

 

Corporate Family

 

Corporate Structure News:

 

Total Corporate Family Members: 2

 

Company Name

Company Type

Location

Country

Industry

Sales
(USD mil)

Employees

Daito Pharmaceutical Co.,Ltd.

Parent

Toyama-Shi

Japan

Pharmaceutical Manufacturing

336.4

560

Daiwa Pharmaceutical Co.,Ltd

Subsidiary

Toyama, Toyama

Japan

Pharmaceutical Manufacturing

44.8

87

 

 

 

Executives Report

 

 

Board of Directors

 

Name

Title

Function

Yoshihiro Narai

 

Chairman of the Board, Representative Director

Chairman

Biography:

Mr. Yoshihiro Narai was named Chairman of the Board and Representative Director in Daito Pharmaceutical Co.,Ltd., effective April 1, 2013. He used to work for Takeda Pharmaceutical Company Limited and served as President and Representative Director in NIHON PHARMACEUTICAL CO., LTD. He obtained his Bachelor's degree in Commerce from Keio University in March 1968.

Age: 68

Education:

Keio University, B (Commerce)

Hideyuki Kato

 

Senior Managing Executive Officer, Chief Director of Drug Substance, Director

Director/Board Member

Biography:

Mr. Hideyuki Kato has been serving as Senior Managing Executive Officer, Chief Director of Drug Substance and Director in Daito Pharmaceutical Co.,Ltd. since August 26, 2011. He joined the Company in April 1971 and used to serve as Director of Drug Substance, Deputy Chief Director of Drug Substance and Managing Executive Officer in the Company.

Age: 66

Junichi Kikuta

 

Managing Executive Officer, Chief Director of Research and Development, Director

Director/Board Member

Biography:

Mr. Junichi Kikuta was named Senior Managing Executive Officer, Chief Director of Research and Development and Director in Daito Pharmaceutical Co.,Ltd., effective August 29, 2013. He joined the Company in March 2010 and previously served as Executive Officer. He used to work for Takeda Pharmaceutical Company Limited.

Age: 63

Yasunobu Ohtsuga

 

President, Representative Director

Director/Board Member

Biography:

Mr. Yasunobu Ohtsuga has been serving as President and Representative Director in Daito Pharmaceutical Co.,Ltd., since August 28, 2012. He joined the Company in March 1975 and served as Director of Sales Planning, Managing Director, Senior Managing Director, Chief Director of Administration, Senior Managing Executive Officer and Manager of Business Planning Office. Mr. Ohtsuga obtained his Bachelor's degree in Pharmacy from Meiji Pharmaceutical University in March 1973.

Age: 62

Education:

Meiji Pharmaceutical University, B (Pharmacy)

 

Executives

 

Name

Title

Function

Yasunobu Ohtsuga

 

President, Representative Director

President

Biography:

Mr. Yasunobu Ohtsuga has been serving as President and Representative Director in Daito Pharmaceutical Co.,Ltd., since August 28, 2012. He joined the Company in March 1975 and served as Director of Sales Planning, Managing Director, Senior Managing Director, Chief Director of Administration, Senior Managing Executive Officer and Manager of Business Planning Office. Mr. Ohtsuga obtained his Bachelor's degree in Pharmacy from Meiji Pharmaceutical University in March 1973.

Age: 62

Education:

Meiji Pharmaceutical University, B (Pharmacy)

Hisao Abe

 

Executive Officer, Director of Finance, Deputy Chief Director of Administration

Division Head Executive

Kenji Fujita

 

Executive Officer, Chief Director of Purchase & Logistics

Division Head Executive

Mitsuo Hirono

 

Executive Officer, Director of Human Resources and General Affairs, Chief Director of Administration

Division Head Executive

Hideyuki Kato

 

Senior Managing Executive Officer, Chief Director of Drug Substance, Director

Division Head Executive

Biography:

Mr. Hideyuki Kato has been serving as Senior Managing Executive Officer, Chief Director of Drug Substance and Director in Daito Pharmaceutical Co.,Ltd. since August 26, 2011. He joined the Company in April 1971 and used to serve as Director of Drug Substance, Deputy Chief Director of Drug Substance and Managing Executive Officer in the Company.

Age: 66

Hiroshi Kawahara

 

Executive Officer, Deputy Chief Director of Production, Manager of Drug Substance Technology Office

Division Head Executive

Kiyotaka Kido

 

Executive Officer, Deputy Chief Director of Production, Director of Production Management

Division Head Executive

Junichi Kikuta

 

Managing Executive Officer, Chief Director of Research and Development, Director

Division Head Executive

Biography:

Mr. Junichi Kikuta was named Senior Managing Executive Officer, Chief Director of Research and Development and Director in Daito Pharmaceutical Co.,Ltd., effective August 29, 2013. He joined the Company in March 2010 and previously served as Executive Officer. He used to work for Takeda Pharmaceutical Company Limited.

Age: 63

Masuo Nomura

 

Executive Officer, Manager of Business Planning Office

Division Head Executive

Kazutaka Nose

 

Executive Officer, Chief Director of Overseas Business

Division Head Executive

Tatsuo Shinohara

 

Executive Officer, Deputy Chief Director of Pharmaceuticals, Director of Medicine

Division Head Executive

Daiki Takeda

 

Executive Officer, Deputy Chief Director of Drug Substance

Division Head Executive

Masamichi Takimoto

 

Managing Executive Officer, Chief Director of Pharmaceuticals, Director of Healthcare

Division Head Executive

Katsuya Tani

 

Executive Officer, Chief Director of Production, Director of Preparation Manufacture

Division Head Executive

Akihiko Yamada

 

Executive Officer, Chief Director of Reliability Assurance

Division Head Executive

Shinjiro Sasayama

 

Director

Other

Biography:

Mr. Shinjiro Sasayama resigned from the position of Director in Daito Pharmaceutical Co.,Ltd. effective August 29, 2013. He is also serving as Director in a subsidiary Daito Pharmaceuticals America, Inc., as well as Chairman of the Board in another company. He joined the Company in July 1970, and served as President, Managing Director, Senior Managing Director, Vice President, Vice Chairman of the Board, Chairman of the Board and Representative Director. He used to work for DENKI KAGAKU KOGYO KABUSHIKI KAISHA.

Age: 73

 

 

Significant Developments

 

 

 

Daito Pharmaceutical Co Ltd to Issue Year-end Dividend for FY 2013

Jul 09, 2013


Daito Pharmaceutical Co Ltd announced that it has decided to issue a year-end dividend of JPY 30 per share, above the latest dividend forecast of JPY 25 per share, disclosed on July 10, 2012, to all the shareholders of record as of May 31, 2013, effective August 30, 2013, for the fiscal year ended May 2013.

Daito Pharmaceutical Co Ltd Appoints New Chairman of the Board

Mar 15, 2013


Daito Pharmaceutical Co Ltd announced that it has appointed Yoshihiro Narai as Chairman of the Board and Representative Director, to replace Shinjiro Sasayama, effective April 1, 2013.

Daito Pharmaceutical Co Ltd Announces Amount of Shares Issued through Private Placement

Mar 15, 2013


Daito Pharmaceutical Co Ltd announced that it has decided to issue 129,000 shares, at the price of JPY 1,195.26 per share, or JPY 154,188,540 in total, through private placement, on March 21, 2013.

Daito Pharmaceutical Co Ltd Announces Issuing Price of New Shares

Feb 13, 2013


Daito Pharmaceutical Co Ltd announced that it will be issuing new shares through public offering at the price of JPY 1,275 per share, or for JPY 1,020,000,000 in total, and through private placement with paid-in price at JPY 1,195.26 per share, or for paid-in amount up to JPY 154,188,540 in total. The new share issuance was previously disclosed on February 4, 2013.

 

 

News

 

Daito Pharmaceutical Co FY Grp Net Pft Y1.79B Vs Y1.39B Pft Yr Earlier
Nikkei English News (80 Words)

09-Jul-2013

Daito Pharmaceutical Co 9Mos Grp Net Pft Y1.13B Vs Y1.09B Pft Yr Earlier
Nikkei English News (79 Words)

09-Apr-2013

Daito Pharmaceutical Co Ltd Appoints New Chairman of the Board
Reuters UK (29 Words)

15-Mar-2013

 

 

Annual Income Statement

 

Financials in: USD (mil) 

Except for share items (millions) and per share items (actual units)

           

 

31-May-2013

31-May-2012

31-May-2011

31-May-2010

31-May-2009

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-May-2013

Updated Normal
31-May-2012

Updated Normal
31-May-2011

Updated Normal
31-May-2010

Updated Normal
30-Nov-2009

Filed Currency

JPY

JPY

JPY

JPY

JPY

Exchange Rate (Period Average)

86.080824

78.698065

83.931161

92.075644

99.54541

Auditor

 

KPMG AZSA LLC

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

 

Unqualified with Explanation

Unqualified

Unqualified

Unqualified with Explanation

 

 

 

 

 

 

    Net Sales

336.4

345.0

300.5

246.3

216.2

Revenue

336.4

345.0

300.5

246.3

216.2

Total Revenue

336.4

345.0

300.5

246.3

216.2

 

 

 

 

 

 

    Cost of Revenue

267.6

273.1

244.5

206.2

180.2

Cost of Revenue, Total

267.6

273.1

244.5

206.2

180.2

Gross Profit

68.8

71.9

56.1

40.1

36.0

 

 

 

 

 

 

    Selling/General/Administrative Expense

37.7

17.1

15.5

12.3

12.1

    Labor & Related Expense

-

6.8

6.4

5.4

4.8

Total Selling/General/Administrative Expenses

37.7

23.9

21.8

17.7

16.8

Research & Development

-

13.2

10.0

5.8

4.5

    Depreciation

-

1.5

0.9

0.9

0.6

    Amortization of Acquisition Costs

0.0

0.0

0.0

0.0

0.0

Depreciation/Amortization

0.0

1.5

0.8

0.9

0.6

    Impairment-Assets Held for Use

0.7

0.4

3.5

0.3

0.3

    Impairment-Assets Held for Sale

-

1.0

0.5

0.1

0.2

    Other Unusual Expense (Income)

-1.4

0.0

-1.6

-0.4

-0.2

Unusual Expense (Income)

-0.7

1.5

2.4

0.0

0.3

    Other Operating Expense

0.0

-

-

-

-

    Other, Net

0.0

0.0

0.1

0.0

0.6

Other Operating Expenses, Total

0.0

0.0

0.1

0.0

0.6

Total Operating Expense

304.5

313.1

279.6

230.5

203.0

 

 

 

 

 

 

Operating Income

31.9

31.9

21.0

15.8

13.2

 

 

 

 

 

 

        Interest Expense - Non-Operating

-1.5

-2.0

-2.2

-2.4

-2.1

    Interest Expense, Net Non-Operating

-1.5

-2.0

-2.2

-2.4

-2.1

        Interest Income - Non-Operating

0.0

0.0

0.0

0.0

0.1

        Investment Income - Non-Operating

-0.6

0.5

0.7

0.5

0.4

    Interest/Investment Income - Non-Operating

-0.6

0.5

0.7

0.5

0.4

Interest Income (Expense) - Net Non-Operating Total

-2.1

-1.5

-1.5

-1.9

-1.7

Gain (Loss) on Sale of Assets

-

0.0

0.0

0.0

-0.2

    Other Non-Operating Income (Expense)

0.5

0.8

0.5

-0.1

0.4

Other, Net

0.5

0.8

0.5

-0.1

0.4

Income Before Tax

30.3

31.2

20.0

13.8

11.7

 

 

 

 

 

 

Total Income Tax

9.5

13.5

8.2

5.6

4.8

Income After Tax

20.7

17.7

11.8

8.2

7.0

 

 

 

 

 

 

    Minority Interest

0.0

-

-

-

0.0

Net Income Before Extraord Items

20.8

17.7

11.8

8.2

7.0

Net Income

20.8

17.7

11.8

8.2

7.0

 

 

 

 

 

 

    Miscellaneous Earnings Adjustment

-

0.0

0.0

-

-

Total Adjustments to Net Income

-

0.0

0.0

-

-

Income Available to Common Excl Extraord Items

20.8

17.7

11.8

8.2

7.0

 

 

 

 

 

 

Income Available to Common Incl Extraord Items

20.8

17.7

11.8

8.2

7.0

 

 

 

 

 

 

Basic/Primary Weighted Average Shares

9.2

9.0

9.0

7.5

6.0

Basic EPS Excl Extraord Items

2.26

1.97

1.32

1.09

1.16

Basic/Primary EPS Incl Extraord Items

2.26

1.97

1.32

1.09

1.16

Dilution Adjustment

-

0.0

0.0

0.0

0.0

Diluted Net Income

20.8

17.7

11.8

8.2

7.0

Diluted Weighted Average Shares

9.2

9.0

9.0

7.5

6.0

Diluted EPS Excl Extraord Items

2.26

1.97

1.32

1.09

1.16

Diluted EPS Incl Extraord Items

2.26

1.97

1.32

1.09

1.16

Dividends per Share - Common Stock Primary Issue

0.35

0.38

0.24

0.16

0.15

Gross Dividends - Common Stock

3.4

3.4

2.1

1.9

1.1

Interest Expense, Supplemental

1.5

2.0

2.2

2.4

2.1

Depreciation, Supplemental

29.8

28.9

25.0

21.2

17.5

Total Special Items

-0.8

1.5

2.4

0.1

0.5

Normalized Income Before Tax

29.5

32.7

22.4

13.8

12.2

 

 

 

 

 

 

Effect of Special Items on Income Taxes

-0.2

0.7

1.0

0.0

0.2

Inc Tax Ex Impact of Sp Items

9.3

14.2

9.2

5.6

5.0

Normalized Income After Tax

20.2

18.5

13.2

8.2

7.2

 

 

 

 

 

 

Normalized Inc. Avail to Com.

20.2

18.5

13.2

8.2

7.2

 

 

 

 

 

 

Basic Normalized EPS

2.20

2.06

1.47

1.09

1.21

Diluted Normalized EPS

2.20

2.06

1.47

1.09

1.21

Amort of Acquisition Costs, Supplemental

0.0

0.0

0.0

0.0

0.0

Research & Development Exp, Supplemental

-

13.2

10.0

5.8

4.5

Reported Operating Profit

31.1

33.4

23.3

15.7

13.4

Reported Ordinary Profit

29.5

32.7

22.4

13.8

11.9

Normalized EBIT

31.1

33.4

23.4

15.8

13.5

Normalized EBITDA

61.0

62.2

48.3

37.0

31.0

    Current Tax - Total

8.9

13.2

-

-

-

Current Tax - Total

8.9

13.2

-

-

-

    Deferred Tax - Total

0.6

0.3

-

-

-

Deferred Tax - Total

0.6

0.3

-

-

-

Income Tax - Total

9.5

13.5

-

-

-

Interest Cost - Domestic

-

0.2

0.2

0.2

0.1

Service Cost - Domestic

-

1.0

0.9

0.7

0.7

Prior Service Cost - Domestic

-

-0.2

-0.2

-0.2

-0.2

Expected Return on Assets - Domestic

-

-0.1

-0.1

-0.1

-0.1

Actuarial Gains and Losses - Domestic

-

0.0

0.3

0.1

0.3

Other Pension, Net - Domestic

-

0.3

0.4

0.1

0.1

Domestic Pension Plan Expense

-

1.1

1.4

0.8

0.9

Total Pension Expense

-

1.1

1.4

0.8

0.9

Discount Rate - Domestic

-

2.00%

2.00%

2.00%

2.00%

Expected Rate of Return - Domestic

-

2.00%

2.00%

2.00%

2.00%

Total Plan Interest Cost

-

0.2

0.2

0.2

0.1

Total Plan Service Cost

-

1.0

0.9

0.7

0.7

Total Plan Expected Return

-

-0.1

-0.1

-0.1

-0.1

Total Plan Other Expense

-

0.3

0.4

0.1

0.1

 

 

Annual Balance Sheet

 

Financials in: USD (mil)

 

 

 

31-May-2013

31-May-2012

31-May-2011

31-May-2010

31-May-2009

UpdateType/Date

Updated Normal
31-May-2013

Updated Normal
31-May-2012

Updated Normal
31-May-2011

Updated Normal
31-May-2010

Updated Normal
30-Nov-2009

Filed Currency

JPY

JPY

JPY

JPY

JPY

Exchange Rate

100.88607

78.981276

81.24

91.035

95.455

Auditor

 

KPMG AZSA LLC

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

 

Unqualified with Explanation

Unqualified

Unqualified

Unqualified with Explanation

 

 

 

 

 

 

    Cash & Equivalents

41.1

19.9

21.6

28.7

12.2

Cash and Short Term Investments

41.1

19.9

21.6

28.7

12.2

        Accounts Receivable - Trade, Gross

92.2

107.9

100.4

76.1

70.8

        Provision for Doubtful Accounts

-0.5

-0.9

-0.9

-1.0

-1.0

    Trade Accounts Receivable - Net

91.6

107.0

99.6

75.1

69.8

    Notes Receivable - Short Term

7.5

5.4

4.9

3.1

2.4

Total Receivables, Net

99.1

112.4

104.4

78.2

72.2

    Inventories - Finished Goods

8.8

7.2

9.7

11.0

12.2

    Inventories - Work In Progress

15.8

20.5

17.7

13.0

14.3

    Inventories - Raw Materials

15.2

15.6

15.5

7.9

6.0

Total Inventory

39.8

43.3

42.9

32.0

32.5

    Deferred Income Tax - Current Asset

3.1

3.1

2.5

2.5

2.6

    Other Current Assets

0.6

0.9

0.3

0.2

0.3

Other Current Assets, Total

3.7

4.0

2.9

2.7

2.9

Total Current Assets

183.7

179.6

171.8

141.5

119.8

 

 

 

 

 

 

    Property/Plant/Equipment - Gross

-

0.0

-

-

-

Property/Plant/Equipment - Net

128.8

168.8

156.6

137.7

133.6

Goodwill, Net

-

-

-

0.0

0.0

Intangibles, Net

5.5

6.1

3.5

1.8

1.6

    LT Investments - Other

23.1

18.1

20.0

19.1

16.9

Long Term Investments

23.1

18.1

20.0

19.1

16.9

    Deferred Income Tax - Long Term Asset

0.3

0.9

1.0

0.2

0.2

    Other Long Term Assets

3.2

5.2

4.9

4.2

4.1

Other Long Term Assets, Total

3.5

6.1

5.8

4.4

4.2

Total Assets

344.6

378.7

357.9

304.5

276.1

 

 

 

 

 

 

Accounts Payable

34.0

40.9

44.4

36.7

37.3

Accrued Expenses

5.2

6.1

5.8

5.0

4.8

Notes Payable/Short Term Debt

40.3

39.1

36.9

32.5

27.0

Current Portion - Long Term Debt/Capital Leases

30.4

36.3

32.7

29.9

25.0

    Income Taxes Payable

2.9

7.7

6.5

2.2

3.8

    Other Payables

21.4

21.2

20.0

17.2

14.0

    Deferred Income Tax - Current Liability

-

-

-

0.0

0.0

    Other Current Liabilities

0.8

3.3

0.7

0.6

1.1

Other Current liabilities, Total

25.1

32.2

27.3

19.9

18.9

Total Current Liabilities

135.1

154.7

147.1

124.2

113.0

 

 

 

 

 

 

    Long Term Debt

48.3

59.5

59.2

50.4

67.7

    Capital Lease Obligations

4.7

10.8

14.8

15.0

16.0

Total Long Term Debt

53.0

70.2

74.1

65.3

83.7

Total Debt

123.7

145.7

143.7

127.8

135.6

 

 

 

 

 

 

    Deferred Income Tax - LT Liability

3.6

0.7

0.7

1.5

1.0

Deferred Income Tax

3.6

0.7

0.7

1.5

1.0

Minority Interest

3.2

-

-

-

-

    Pension Benefits - Underfunded

2.1

3.3

4.1

4.3

4.7

    Other Long Term Liabilities

1.4

4.0

4.2

3.2

3.3

Other Liabilities, Total

3.5

7.3

8.3

7.5

8.0

Total Liabilities

198.4

232.9

230.2

198.5

205.7

 

 

 

 

 

 

    Common Stock

30.9

32.5

31.6

28.2

15.1

Common Stock

30.9

32.5

31.6

28.2

15.1

Additional Paid-In Capital

29.8

31.0

30.2

26.9

13.9

Retained Earnings (Accumulated Deficit)

77.6

79.9

62.8

47.1

38.2

Treasury Stock - Common

0.0

0.0

0.0

0.0

0.0

Unrealized Gain (Loss)

6.4

2.4

3.1

3.7

3.2

    Translation Adjustment

1.5

0.0

0.0

0.0

0.0

    Other Equity

-

0.0

-

-

-

Other Equity, Total

1.5

0.0

0.0

0.0

0.0

Total Equity

146.2

145.8

127.6

105.9

70.3

 

 

 

 

 

 

Total Liabilities & Shareholders’ Equity

344.6

378.7

357.9

304.5

276.1

 

 

 

 

 

 

    Shares Outstanding - Common Stock Primary Issue

9.9

9.0

9.0

9.0

7.2

Total Common Shares Outstanding

9.9

9.0

9.0

9.0

7.2

Treasury Shares - Common Stock Primary Issue

0.0

0.0

0.0

0.0

0.0

Employees

-

560

554

541

504

Number of Common Shareholders

-

2,662

1,944

1,702

315

Total Long Term Debt, Supplemental

-

91.3

87.7

77.0

89.9

Long Term Debt Maturing within 1 Year

-

31.8

28.5

26.6

22.2

Long Term Debt Maturing in Year 2

-

27.0

24.2

19.8

24.1

Long Term Debt Maturing in Year 3

-

18.5

19.5

15.5

18.2

Long Term Debt Maturing in Year 4

-

11.3

10.9

10.7

13.1

Long Term Debt Maturing in Year 5

-

2.6

4.0

4.1

8.3

Long Term Debt Maturing in 2-3 Years

-

45.4

43.6

35.3

42.3

Long Term Debt Maturing in 4-5 Years

-

13.9

14.9

14.8

21.4

Long Term Debt Matur. in Year 6 & Beyond

-

0.2

0.6

0.2

4.0

Total Capital Leases, Supplemental

-

15.3

19.1

18.3

18.8

Capital Lease Payments Due in Year 1

-

4.5

4.2

3.3

2.8

Capital Lease Payments Due in Year 2

-

5.2

4.4

3.4

2.9

Capital Lease Payments Due in Year 3

-

2.9

5.0

3.5

3.0

Capital Lease Payments Due in Year 4

-

2.4

2.8

3.9

3.1

Capital Lease Payments Due in Year 5

-

0.2

2.3

2.2

3.3

Capital Lease Payments Due in 2-3 Years

-

8.0

9.4

6.9

5.8

Capital Lease Payments Due in 4-5 Years

-

2.6

5.1

6.2

6.4

Cap. Lease Pymts. Due in Year 6 & Beyond

-

0.1

0.3

1.9

3.8

Pension Obligation - Domestic

-

10.3

10.1

9.2

8.0

Plan Assets - Domestic

-

7.4

6.5

5.3

4.0

Funded Status - Domestic

-

-2.9

-3.6

-3.9

-4.1

Total Funded Status

-

-2.9

-3.6

-3.9

-4.1

Discount Rate - Domestic

-

2.00%

2.00%

2.00%

2.00%

Expected Rate of Return - Domestic

-

2.00%

2.00%

2.00%

2.00%

Prepaid Benefits - Domestic

-

0.0

-

-

-

Accrued Liabilities - Domestic

-

-3.2

-4.0

-4.2

-4.6

Other Assets, Net - Domestic

-

-0.3

-0.4

-0.3

-0.6

Net Assets Recognized on Balance Sheet

-

-3.6

-4.4

-4.4

-5.2

Total Plan Obligations

-

10.3

10.1

9.2

8.0

Total Plan Assets

-

7.4

6.5

5.3

4.0

 

 

Annual Cash Flows

 

Financials in: USD (mil)

 

 

 

31-May-2013

31-May-2012

31-May-2011

31-May-2010

31-May-2009

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-May-2013

Updated Normal
31-May-2012

Updated Normal
31-May-2011

Updated Normal
31-May-2010

Updated Normal
30-Nov-2009

Filed Currency

JPY

JPY

JPY

JPY

JPY

Exchange Rate (Period Average)

86.080824

78.698065

83.931161

92.075644

99.54541

Auditor

 

KPMG AZSA LLC

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

 

Unqualified with Explanation

Unqualified

Unqualified

Unqualified with Explanation

 

 

 

 

 

 

Net Income/Starting Line

30.3

31.2

20.0

13.8

11.7

    Depreciation

29.8

28.9

25.0

21.2

17.5

Depreciation/Depletion

29.8

28.9

25.0

21.2

17.5

    Amortization of Acquisition Costs

0.0

0.0

0.0

0.0

0.0

Amortization

0.0

0.0

0.0

0.0

0.0

    Unusual Items

-0.8

1.5

3.4

0.0

0.5

    Other Non-Cash Items

-0.3

-0.1

0.3

0.8

1.6

Non-Cash Items

-1.1

1.3

3.7

0.8

2.1

    Accounts Receivable

-12.7

-5.0

-16.1

-2.2

-15.7

    Inventories

-7.0

0.7

-6.9

2.1

2.3

    Accounts Payable

5.6

-4.3

13.5

-6.8

-6.7

    Accrued Expenses

-0.1

0.1

0.2

0.0

0.0

    Other Operating Cash Flow

-15.4

-10.3

-5.7

-5.3

-1.0

Changes in Working Capital

-29.5

-18.9

-14.9

-12.2

-21.1

Cash from Operating Activities

29.5

42.5

33.7

23.5

10.3

 

 

 

 

 

 

    Purchase of Fixed Assets

-21.6

-37.3

-36.5

-13.6

-46.8

Capital Expenditures

-21.6

-37.3

-36.5

-13.6

-46.8

    Sale of Business

0.7

-

-

-

-

    Sale of Fixed Assets

1.6

0.3

0.0

0.0

0.0

    Sale/Maturity of Investment

0.1

0.1

0.1

1.6

1.3

    Purchase of Investments

-7.7

-0.2

-1.1

-1.5

-4.5

    Other Investing Cash Flow

0.9

-3.3

-2.2

-0.3

-0.6

Other Investing Cash Flow Items, Total

-4.4

-3.1

-3.2

-0.2

-3.8

Cash from Investing Activities

-26.0

-40.4

-39.7

-13.8

-50.6

 

 

 

 

 

 

    Other Financing Cash Flow

0.0

0.0

-

-

-

Financing Cash Flow Items

0.0

0.0

-

-

-

    Cash Dividends Paid - Common

-3.1

-2.3

-2.1

-1.2

-0.4

Total Cash Dividends Paid

-3.1

-2.3

-2.1

-1.2

-0.4

        Sale/Issuance of Common

12.8

-

0.0

24.2

21.3

        Repurchase/Retirement of Common

0.0

0.0

0.0

0.0

0.0

    Common Stock, Net

12.8

0.0

0.0

24.2

21.3

Issuance (Retirement) of Stock, Net

12.8

0.0

0.0

24.2

21.3

    Short Term Debt, Net

11.4

1.2

0.4

4.2

-8.3

        Long Term Debt Issued

36.6

35.6

32.8

13.0

51.8

        Long Term Debt Reduction

-38.0

-38.8

-35.2

-33.2

-22.5

    Long Term Debt, Net

-1.4

-3.3

-2.5

-20.2

29.4

Issuance (Retirement) of Debt, Net

10.0

-2.1

-2.0

-16.0

21.0

Cash from Financing Activities

19.6

-4.4

-4.2

7.0

41.9

 

 

 

 

 

 

Foreign Exchange Effects

1.5

0.0

0.0

0.0

0.0

Net Change in Cash

24.7

-2.3

-10.2

16.7

1.6

 

 

 

 

 

 

Net Cash - Beginning Balance

18.3

22.3

31.1

11.6

9.1

Net Cash - Ending Balance

43.0

20.0

20.9

28.3

10.7

Cash Interest Paid

1.5

2.0

2.2

2.4

2.1

Cash Taxes Paid

12.6

12.2

5.0

7.0

5.5

 

 

Annual Income Statement

 

Financials in: USD (mil) 

Except for share items (millions) and per share items (actual units)         

 

 

31-May-2013

31-May-2012

31-May-2011

31-May-2010

31-May-2009

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-May-2013

Updated Normal
31-May-2012

Updated Normal
31-May-2011

Updated Normal
31-May-2010

Updated Normal
30-Nov-2009

Filed Currency

JPY

JPY

JPY

JPY

JPY

Exchange Rate (Period Average)

86.080824

78.698065

83.931161

92.075644

99.54541

Auditor

 

KPMG AZSA LLC

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

 

Unqualified with Explanation

Unqualified

Unqualified

Unqualified with Explanation

 

 

 

 

 

 

    Revenues

336.4

345.0

300.5

246.3

216.2

Total Revenue

336.4

345.0

300.5

246.3

216.2

 

 

 

 

 

 

    Rounding adjustment Income Statement

0.0

-

-

-

-

    Total cost of sales

267.6

273.1

244.5

206.2

180.2

    Reversal of provision for sales returns

0.0

-

-

-

-

    Provision for sales returns

-

0.0

-

-

-

    Reversal of reserve for returns

-

-

0.0

-0.4

0.0

    Provision for reserve for returns

-

-

0.1

0.4

0.6

    Salaries

-

6.6

-

-

-

    Bonuses and Provision for Bonuses - SGA

-

0.1

-

-

-

    Directors' Compensation

-

0.1

-

-

-

    Payrolls

-

-

6.3

5.4

4.7

    Provision for bonuses

-

-

0.1

0.0

0.0

    Selling, general and administrative expe

37.7

-

-

-

-

    Bad Debt Exp&Prov of Allow.-Dbt Acct-SGA

-

0.0

-

-

-

    Other Selling/General/Admin. Expense

-

17.1

-

-

-

    Provision for doubtful accounts(SGA)

-

-

0.2

0.0

0.2

    Depreciation - SGA

-

1.5

-

-

-

    Depreciation expenses

-

-

0.9

0.9

0.6

    Amortization of goodwill

-

-

-

0.0

0.0

    Research and Development Expense(in SGA)

-

13.2

-

-

-

    R & D expenses

-

-

10.0

5.8

4.5

    Othere SGA expenses

-

-

15.3

12.2

11.9

    Rounding adjustment Income Statement

0.0

-

-

-

-

    Insurance income

-0.8

-

-

-

-

    Gain On Negative Goodwill

-0.7

-

-

-

-

    SP Susidy income

0.0

-0.1

-1.6

-2.3

-0.9

    SP Compensation income

-

0.0

-1.5

0.0

-

    SP Other special income

-

0.0

-0.3

-0.1

-0.1

    SP L. on retire. of fixed assets

0.7

0.4

0.7

0.3

0.3

    SP L on val. of LT inv't. secs.

-

1.0

0.5

0.1

0.2

    SP L on cancel. of derivative contract

-

-

-

-

0.0

    SP L on deduction fixed assets

0.0

0.1

1.5

2.1

0.7

    SP Assets impairment losses

-

0.0

2.8

0.0

-

    SP Other special expenses

0.0

0.0

0.3

0.0

0.1

    NOP Amortization of negative goodwill

0.0

0.0

0.0

0.0

0.0

Total Operating Expense

304.5

313.1

279.6

230.5

203.0

 

 

 

 

 

 

    NOP Interest income

0.0

0.0

0.0

0.0

0.1

    Foreign exchange losses

-1.1

-

-

-

-

    NOP Dividends received

0.4

0.5

0.4

0.3

0.3

    NOP Foreign exchange gains

-

0.1

0.3

0.2

0.0

    Reversal of allowance for doubtful accou

0.1

-

-

-

-

    Other Non-Operating Income (Expense)

0.0

0.0

-

-

-

    NOP Rental income

0.2

0.2

0.2

0.2

0.2

    NOP Guarantee income

0.3

0.4

0.2

0.2

0.2

    NOP Insurance income

0.1

0.4

0.0

0.1

0.2

    NOP Other non-operating income

0.1

0.3

0.2

0.2

0.1

    NOP Interest expenses

-1.5

-2.0

-2.2

-2.4

-2.1

    NOP IPO expenses

-

-

0.0

-0.4

0.0

    NOP Amortization of bond issue expenses

-

-

-

-

0.0

    NOP L on sale of trade notes rcvbl.

-

-

-

0.0

-0.2

    NOP Other non-operating expenses

-0.3

-0.5

-0.2

-0.4

-0.3

    SP G on sale of LT inv't. secs.

0.0

0.0

0.0

0.0

0.1

    SP G on sale of fixed assets

-

0.0

0.0

0.0

0.0

    SP L on sale of fixed assets

-

0.0

0.0

0.0

0.0

    SP L on sale of LT inv't. secs.

-

-

0.0

0.0

0.0

Net Income Before Taxes

30.3

31.2

20.0

13.8

11.7

 

 

 

 

 

 

Total income taxes

9.5

13.5

8.2

5.6

4.8

Net Income After Taxes

20.7

17.7

11.8

8.2

7.0

 

 

 

 

 

 

    Minority interests in loss

0.0

-

-

-

-

    Minority interest

-

-

-

-

0.0

Net Income Before Extra. Items

20.8

17.7

11.8

8.2

7.0

Net Income

20.8

17.7

11.8

8.2

7.0

 

 

 

 

 

 

    Rounding adjustment Income Statement

-

0.0

-

-

-

    Adjustment

-

-

0.0

-

-

Income Available to Com Excl ExtraOrd

20.8

17.7

11.8

8.2

7.0

 

 

 

 

 

 

Income Available to Com Incl ExtraOrd

20.8

17.7

11.8

8.2

7.0

 

 

 

 

 

 

Basic Weighted Average Shares

9.2

9.0

9.0

7.5

6.0

Basic EPS Excluding ExtraOrdinary Items

2.26

1.97

1.32

1.09

1.16

Basic EPS Including ExtraOrdinary Items

2.26

1.97

1.32

1.09

1.16

Dilution Adjustment

-

0.0

0.0

0.0

0.0

Diluted Net Income

20.8

17.7

11.8

8.2

7.0

Diluted Weighted Average Shares

9.2

9.0

9.0

7.5

6.0

Diluted EPS Excluding ExtraOrd Items

2.26

1.97

1.32

1.09

1.16

Diluted EPS Including ExtraOrd Items

2.26

1.97

1.32

1.09

1.16

DPS-Ordinary Shares

0.35

0.38

0.24

0.16

0.15

Gross Dividends - Common Stock

3.4

3.4

2.1

1.9

1.1

Normalized Income Before Taxes

29.5

32.7

22.4

13.8

12.2

 

 

 

 

 

 

Inc Tax Ex Impact of Sp Items

9.3

14.2

9.2

5.6

5.0

Normalized Income After Taxes

20.2

18.5

13.2

8.2

7.2

 

 

 

 

 

 

Normalized Inc. Avail to Com.

20.2

18.5

13.2

8.2

7.2

 

 

 

 

 

 

Basic Normalized EPS

2.20

2.06

1.47

1.09

1.21

Diluted Normalized EPS

2.20

2.06

1.47

1.09

1.21

Interest expenses

1.5

2.0

2.2

2.4

2.1

BC - Depreciation of Fixed Assets

29.8

-

-

-

-

Depreciation - SGA

-

28.9

-

-

-

Depreciation

-

-

25.0

21.2

17.5

BC - Depreciation of Goodwill

0.0

-

-

-

-

Amort. of goodwill

-

-

0.0

0.0

0.0

Amort. of negative goodwill

-

0.0

0.0

0.0

0.0

Research and Development Expense(in SGA)

-

13.2

-

-

-

R & D expenses ( SGA )

-

-

10.0

5.8

4.5

    Income taxes-current

8.9

13.2

-

-

-

Current Tax - Total

8.9

13.2

-

-

-

    Income taxes-deferred

0.6

0.3

-

-

-

Deferred Tax - Total

0.6

0.3

-

-

-

Income Tax - Total

9.5

13.5

-

-

-

Reported Operating Profit

31.1

33.4

23.3

15.7

13.4

Reported Ordinary Profit

29.5

32.7

22.4

13.8

11.9

Service Cost

-

1.0

-

-

-

Service Cost

-

-

0.9

0.7

0.7

Interest Cost

-

0.2

-

-

-

Interest Cost

-

-

0.2

0.2

0.1

Expected Return on Pension Assets

-

-0.1

-

-

-

Expected Return on Plan Assets

-

-

-0.1

-0.1

-0.1

Recognized Actuarial Gain and Loss

-

0.0

-

-

-

Actuarial Gains and Losses

-

-

0.3

0.1

0.3

Amortization of Prior Service Cost

-

-0.2

-

-

-

Prior Service Cost

-

-

-0.2

-0.2

-0.2

Extraordinary Additional Other Retiremen

-

0.1

-

-

-

Temporary retirement expense

-

0.2

-

-

-

Nonrecurr. additional retire. benefits

-

-

0.3

0.0

-

S&M enterprise retire.allow.cooperative

-

-

0.1

0.1

0.1

Domestic Pension Plan Expense

-

1.1

1.4

0.8

0.9

Total Pension Expense

-

1.1

1.4

0.8

0.9

Discount Rate(MIN)-Retirement Cost(Domes

-

2.00%

-

-

-

Discount Rate

-

-

2.00%

2.00%

2.00%

Expected return on assets(MIN)-Retiremen

-

2.00%

-

-

-

Expected Rate of Return

-

-

2.00%

2.00%

2.00%

 

 

Annual Balance Sheet

 

Financials in: USD (mil)

 

 

 

31-May-2013

31-May-2012

31-May-2011

31-May-2010

31-May-2009

UpdateType/Date

Updated Normal
31-May-2013

Updated Normal
31-May-2012

Updated Normal
31-May-2011

Updated Normal
31-May-2010

Updated Normal
30-Nov-2009

Filed Currency

JPY

JPY

JPY

JPY

JPY

Exchange Rate

100.88607

78.981276

81.24

91.035

95.455

Auditor

 

KPMG AZSA LLC

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

 

Unqualified with Explanation

Unqualified

Unqualified

Unqualified with Explanation

 

 

 

 

 

 

    Cash & deposits

41.1

19.9

21.6

28.7

12.2

    Accounts & notes receivable, gross

92.2

107.9

100.4

76.1

70.8

    Electronically recorded monetary claims-

3.5

-

-

-

-

    Merchandise & finished goods

8.8

7.2

9.7

11.0

12.2

    Inventories - construc.-in-process

15.8

20.5

17.7

13.0

14.3

    Raw materials & supplies

15.2

15.6

15.5

7.9

6.0

    Deferred income taxes (current)

3.1

3.1

2.5

2.5

2.6

    Factoring receivables

4.0

5.4

4.9

3.1

2.4

    Rounding adjustment Assets

-

0.0

-

-

-

    Other current assets

0.6

0.9

0.3

0.2

0.3

    Allow.doubt.accounts (current)

-0.5

-0.9

-0.9

-1.0

-1.0

Total Current Assets

183.7

179.6

171.8

141.5

119.8

 

 

 

 

 

 

    Buildings and structures, net

69.0

-

-

-

-

    Machinery, equipment and vehicles, net

36.9

-

-

-

-

    Other, net

2.6

-

-

-

-

    Buildings & structures, net

-

84.4

83.7

71.2

73.1

    Machineries, equipment, &vehicles, net

-

34.5

36.9

25.5

27.3

    Land

12.0

15.3

14.9

13.3

12.7

    Lease assets

7.8

12.8

15.9

17.7

18.4

    Construction-in-progress

0.5

18.4

2.3

7.5

0.2

    Other PPE

-

3.3

2.9

2.5

1.8

    Goodwill

-

-

-

0.0

0.0

    Lease assets

0.0

0.1

0.2

0.2

0.3

    Other intangibles

5.5

6.0

3.4

1.6

1.4

    Long-term investment in securities

23.1

18.1

20.0

19.1

16.9

    Other

3.6

-

-

-

-

    Other Long Term Assets

-

0.0

-

-

-

    Deferred inc. taxes (non-current)

0.3

0.9

1.0

0.2

0.2

    Other assets

-

6.0

5.7

4.8

4.8

    Allow.doubt.accounts (non-current)

-0.5

-0.8

-0.9

-0.7

-0.7

    Other ppe. met

-

0.0

-

-

-

Total Assets

344.6

378.7

357.9

304.5

276.1

 

 

 

 

 

 

    Trade accounts & notes payable

31.6

38.0

39.8

26.9

31.2

    Short-term borrowings

40.3

39.1

36.9

32.5

27.0

    LTD within one year

25.2

-

-

-

-

    Current portion of bonds

1.0

1.6

-

-

-

    LT borrowings (current)

-

30.2

28.5

21.7

20.9

    Straight bonds (current)

-

-

0.0

5.0

1.4

    Current lease obligations

4.2

4.5

4.2

3.3

2.8

    Income taxes payable

2.9

7.7

6.5

2.2

3.8

    Deferred tax liabilities (current)

-

-

-

0.0

0.0

    Reserve for bonuses

0.5

0.7

0.6

0.4

0.3

    Reserve for directors' bonuses

-

0.1

0.1

0.0

0.0

    Rounding adjustment Liability

-

0.0

-

-

-

    Reserve for sales return

0.2

0.3

0.3

0.4

0.7

    Other accounts payable

5.9

5.8

3.7

6.5

2.8

    Accrued expenses

4.7

5.4

5.1

4.7

4.5

    Factoring payable

15.5

15.4

16.3

10.7

11.2

    Construction notes payable

2.5

2.8

4.6

9.8

6.1

    Other liabilities

0.6

3.1

0.4

0.2

0.4

Total Current Liabilities

135.1

154.7

147.1

124.2

113.0

 

 

 

 

 

 

    Straight bonds

-

1.3

2.8

0.9

4.7

    LT borrowings

48.3

58.2

56.4

49.5

63.0

    Lease obligations

4.7

10.8

14.8

15.0

16.0

Total Long Term Debt

53.0

70.2

74.1

65.3

83.7

 

 

 

 

 

 

    Deferred tax liabilities (non-current)

3.6

0.7

0.7

1.5

1.0

    Reserve for accrued retirement benefit

2.1

3.2

4.0

4.2

4.6

    Reserve for officers' retirement

-

0.1

0.1

0.1

0.1

    Other Long Term Liabilities

-

0.0

-

-

-

    Negative goodwill

-

0.0

0.0

0.1

0.1

    Other liabilities

1.4

4.0

4.2

3.1

3.2

    Minority interests

3.2

-

-

-

-

Total Liabilities

198.4

232.9

230.2

198.5

205.7

 

 

 

 

 

 

    Rounding adjustment Equity

-

0.0

-

-

-

    Common stock

30.9

32.5

31.6

28.2

15.1

    Total capital surpluses

29.8

31.0

30.2

26.9

13.9

    Total retained earnings

77.6

79.9

62.8

47.1

38.2

    Treasury stocks

0.0

0.0

0.0

0.0

0.0

    Reserve by val. of investment sec.

6.4

2.4

3.1

3.7

3.2

    Deferred hedge gain/loss

-

-

-

-

0.0

    Cumulative translation adjustments

1.5

0.0

0.0

0.0

0.0

Total Equity

146.2

145.8

127.6

105.9

70.3

 

 

 

 

 

 

Total Liabilities & Shareholders' Equity

344.6

378.7

357.9

304.5

276.1

 

 

 

 

 

 

    S/O-Ordinary Shares

9.9

9.0

9.0

9.0

7.2

Total Common Shares Outstanding

9.9

9.0

9.0

9.0

7.2

T/S-Ordinary Shares

0.0

0.0

0.0

0.0

0.0

Total Number of Employee

-

560

-

-

-

Full time employees

-

-

554

541

504

Total Number of Shareholders

-

2,662

-

-

-

Number of Common Shareholders

-

-

1,944

1,702

315

Bond Redemption Amounts within A Year

-

1.6

-

-

-

Loans Payable Maturing within a Year

-

30.2

-

-

-

Bond & LT Debt maturing within 1 year

-

-

28.5

26.6

22.2

Bond Redemp Amts over a Yr within 2 Yrs

-

1.3

-

-

-

Lns Pble Maturing over a Yr within 2 Yrs

-

25.7

-

-

-

Bond & LT Debt maturing in year 2

-

-

24.2

19.8

24.1

Lns Pble Maturg over 2 Yrs within 3 Yrs

-

18.5

-

-

-

Bond & LT Debt maturing in year 3

-

-

19.5

15.5

18.2

Lns Pble Maturg over 3 Yrs within 4 Yrs

-

11.3

-

-

-

Bond & LT Debt maturing in year 4

-

-

10.9

10.7

13.1

Lns Pble Maturg over 4 Yrs within 5 Yrs

-

2.6

-

-

-

Bond & LT Debt maturing in year 5

-

-

4.0

4.1

8.3

Othe lt debt, remaing

-

0.2

-

-

-

Bond & LT Debt - remaining maturities

-

-

0.6

0.2

4.0

Total Long Term Debt, Supplemental

-

91.3

87.7

77.0

89.9

Capital Lease Maturing within a Year

-

4.5

-

-

-

Capital lease payment within 1 year

-

-

4.2

3.3

2.8

Cap Lease Maturg over a Yr within 2 Yrs

-

5.2

-

-

-

Capital lease payment in year 2

-

-

4.4

3.4

2.9

Cap Lease Maturg over 2 Yr within 3 Yrs

-

2.9

-

-

-

Capital lease payment in year 3

-

-

5.0

3.5

3.0

Cap Lease Maturg over 3 Yr within 4 Yrs

-

2.4

-

-

-

Capital lease payment in year 4

-

-

2.8

3.9

3.1

Cap Lease Maturg over 4 Yr within 5 Yrs

-

0.2

-

-

-

Capital lease payment in year 5

-

-

2.3

2.2

3.3

other capiotal lease

-

0.1

-

-

-

Capital lease - remaining maturities

-

-

0.3

1.9

3.8

Total Capital Leases, Supplemental

-

15.3

19.1

18.3

18.8

Projected Retirement Benefit Obligation

-

10.3

-

-

-

Pension Obligation

-

-

10.1

9.2

8.0

Plan Assets at Fair Value

-

7.4

-

-

-

Fair Value of Plan Assets

-

-

6.5

5.3

4.0

Unfunded Retirement Benefit Obligation

-

-2.9

-

-

-

Funded Status

-

-

-3.6

-3.9

-4.1

Total Funded Status

-

-2.9

-3.6

-3.9

-4.1

Discount Rate - Period End

-

2.00%

-

-

-

Discount Rate

-

-

2.00%

2.00%

2.00%

Expected Rate of Return - Period End

-

2.00%

-

-

-

Expected Rate of Return

-

-

2.00%

2.00%

2.00%

Prepaid Pension Expense

-

0.0

-

-

-

Unrecognized Actuarial Gain and Loss

-

-0.1

-

-

-

Unrecognized Prior Service Cost

-

-0.2

-

-

-

Unrecognized Actuarial Gains and Losses

-

-

0.0

0.3

0.1

Unrecognized Prior Service Cost

-

-

-0.4

-0.5

-0.7

Accrued Retirement Benefits

-

-3.2

-

-

-

Reserve for Accrued Retirement Benefits

-

-

-4.0

-4.2

-4.6

Net Assets Recognized on Balance Sheet

-

-3.6

-4.4

-4.4

-5.2

 

 

Annual Cash Flows

 

Financials in: USD (mil)

 

 

 

31-May-2013

31-May-2012

31-May-2011

31-May-2010

31-May-2009

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-May-2013

Updated Normal
31-May-2012

Updated Normal
31-May-2011

Updated Normal
31-May-2010

Updated Normal
30-Nov-2009

Filed Currency

JPY

JPY

JPY

JPY

JPY

Exchange Rate (Period Average)

86.080824

78.698065

83.931161

92.075644

99.54541

Auditor

 

KPMG AZSA LLC

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

 

Unqualified with Explanation

Unqualified

Unqualified

Unqualified with Explanation

 

 

 

 

 

 

Net Income

30.3

31.2

20.0

13.8

11.7

    Depreciation

29.8

28.9

25.0

21.2

17.5

    Amortization of goodwill

-

-

0.0

0.0

0.0

    Amortization of negative goodwill

0.0

0.0

0.0

0.0

0.0

    Gain on negative goodwill

-0.7

-

-

-

-

    Other Unusual included in Other Noncash

-0.8

-

-

-

-

    Loss (gain) on valuation of investment s

-

1.0

-

-

-

    L on retire. of fixed assets

0.7

0.4

0.7

0.3

0.3

    Loss on reduction of noncurrent assets

0.0

0.1

1.5

2.1

0.0

    Impairment loss

-

0.0

2.8

0.0

-

    Reserve for doubtful accounts

-0.2

-0.1

-0.2

-0.2

0.2

    Reserve for bonuses

0.0

0.0

0.2

0.0

0.0

    Reserve for directors' bonuses

-0.1

0.0

0.1

0.0

-0.1

    Reserve for returned products

0.0

0.0

-0.2

-0.4

0.2

    Reserve for retirement benefits

-0.5

-0.9

-0.7

-0.7

-0.2

    Reserve for dir.'s retire. bonuse

-0.1

-0.1

0.0

0.0

0.0

    Other Operating Cash Flow

0.0

-

-

-

-

    Rounding adjustment Cash flow

-

0.0

-

-

-

    Interest & dividend income

-0.4

-0.5

-0.4

-0.3

-0.3

    Rental income

-0.2

-0.2

-0.2

-0.2

-0.2

    Guarantee income

-0.3

-0.4

-0.2

-0.2

-0.2

    Going public expenses

-

-

0.0

0.4

0.0

    Reversal of interest expenses

1.5

2.0

2.2

2.4

2.1

    L on sale of trade notes rcvbl.

-

-

-

0.0

0.2

    Subsidy income

0.0

-0.1

-1.6

-2.3

0.0

    L on cancel. of derivative contract

-

-

-

-

0.0

    (Inc) Dec accounts receivable

-12.7

-5.0

-16.1

-2.2

-15.7

    (Inc) Dec inventories

-7.0

0.7

-6.9

2.1

2.3

    Inc (Dec) in acts & notes payable

5.6

-4.3

13.5

-6.8

-6.7

    Other operating activities

-1.8

3.1

-2.0

1.5

2.3

    Int & div.received(cash basis)

0.4

0.5

0.4

0.3

0.3

    Interest paid (cash basis)

-1.5

-2.0

-2.2

-2.4

-2.1

    Payment of the stock market flotation ex

-

-

0.0

-0.4

0.0

    Proceeds from subsidy

0.0

0.1

1.6

2.3

0.0

    Guarantee received

-

-

-

0.0

3.1

    Paid on cancel. of derivative contract

-

-

-

-

0.0

    Other received/paid

0.0

0.2

1.4

0.3

0.8

    Income taxes paid or refund

-12.6

-12.2

-5.0

-7.0

-5.5

Cash from Operating Activities

29.5

42.5

33.7

23.5

10.3

 

 

 

 

 

 

    Proceeds from purchase of investments in

0.7

-

-

-

-

    Capital expenditure

-21.6

-37.3

-36.5

-13.6

-46.8

    Sale of PPE

1.6

0.3

0.0

0.0

0.0

    Purch. of LT investment in secs.

-2.9

-0.1

-1.0

-1.0

-3.3

    Sale of LT investment in secs.

0.1

0.0

0.0

0.1

0.2

    Time deposit made

-4.8

0.0

-0.1

-0.5

-1.2

    Time deposit matured

-

0.1

0.1

1.5

1.1

    Proceeds from maturity of insurance fund

2.1

-

-

-

-

    Other investing activities

-1.1

-3.3

-2.2

-0.3

-0.6

Cash from Investing Activities

-26.0

-40.4

-39.7

-13.8

-50.6

 

 

 

 

 

 

    Rounding adjustment Cash flow

0.0

0.0

-

-

-

    ST debt, net

11.4

1.2

0.4

4.2

-8.3

    LT debt issued

36.6

35.6

31.0

12.2

35.5

    LT debt repaid

-32.2

-34.5

-26.0

-28.8

-19.9

    Bond issued

-

0.0

1.8

0.9

0.0

    Bond repaid

-1.5

0.0

-5.4

-1.4

-1.3

    Treasury stock purchased

0.0

0.0

0.0

0.0

0.0

    Cash dividends paid

-3.1

-2.3

-2.1

-1.2

-0.4

    Proceed from sale and lease back

-

-

-

0.0

16.4

    Proceeds from issuance of common stock

12.8

-

-

-

-

    Stocks issued

-

-

0.0

24.2

21.3

    Lease obligation repaid

-4.2

-4.4

-3.8

-3.1

-1.3

Cash from Financing Activities

19.6

-4.4

-4.2

7.0

41.9

 

 

 

 

 

 

Foreign Exchange Effects

1.5

0.0

0.0

0.0

0.0

Net Change in Cash

24.7

-2.3

-10.2

16.7

1.6

 

 

 

 

 

 

Net cash - beginning balance

18.3

22.3

31.1

11.6

9.1

Net cash - ending balance

43.0

20.0

20.9

28.3

10.7

    Cash Interest Paid

1.5

2.0

2.2

2.4

2.1

    Cash Taxes Paid

12.6

12.2

5.0

7.0

5.5

 

 

Financial Health

 

Financials in: USD (mil) 

Except for share items (millions) and per share items (actual units)

 

Key Indicators USD (mil)

 

Quarter
Ending
31-May-2013

Quarter
Ending
Yr Ago

Annual
Year End
31-May-2013

1 Year
Growth

3 Year
Growth

5 Year
Growth

Total Revenue1 (?)

79.8

5.47%

336.4

6.65%

8.49%

6.89%

Operating Income1 (?)

8.5

38.30%

31.9

9.20%

23.67%

16.30%

Income Available to Common Excl Extraord Items1 (?)

6.8

117.55%

20.8

28.61%

33.41%

18.90%

Basic EPS Excl Extraord Items1 (?)

0.70

102.85%

2.26

25.16%

24.63%

5.38%

Capital Expenditures2 (?)

21.6

-

21.6

-36.68%

14.13%

-13.46%

Cash from Operating Activities2 (?)

29.5

-

29.5

-23.98%

5.45%

11.60%

Free Cash Flow (?)

6.8

-

6.8

67.76%

-9.37%

-

Total Assets3 (?)

344.6

16.22%

344.6

16.22%

7.84%

9.29%

Total Liabilities3 (?)

198.4

8.80%

198.4

8.80%

3.46%

1.94%

Total Long Term Debt3 (?)

53.0

-3.62%

53.0

-3.62%

-3.49%

0.23%

Total Common Shares Outstanding3 (?)

9.9

10.37%

9.9

10.37%

3.34%

14.35%

1-ExchangeRate: JPY to USD Average for Period

97.661577

 

86.080824

 

 

 

2-ExchangeRate: JPY to USD Average for Period

86.080824

 

86.080824

 

 

 

3-ExchangeRate: JPY to USD Period End Date

100.886070

 

100.886070

 

 

 

Key Ratios

 

31-May-2013

31-May-2012

31-May-2011

31-May-2010

31-May-2009

Profitability

Gross Margin (?)

20.46%

20.85%

18.66%

16.29%

16.66%

Operating Margin (?)

9.48%

9.25%

6.97%

6.40%

6.11%

Pretax Margin (?)

9.01%

9.04%

6.65%

5.59%

5.43%

Net Profit Margin (?)

6.17%

5.12%

3.93%

3.32%

3.22%

Financial Strength

Current Ratio (?)

1.36

1.16

1.17

1.14

1.06

Long Term Debt/Equity (?)

0.36

0.48

0.58

0.62

1.19

Total Debt/Equity (?)

0.85

1.00

1.13

1.21

1.93

Management Effectiveness

Return on Assets (?)

5.52%

4.71%

3.49%

2.78%

2.85%

Return on Equity (?)

13.60%

12.70%

9.90%

9.20%

12.80%

Efficiency

Receivables Turnover (?)

3.07

3.13

3.23

3.24

3.55

Inventory Turnover (?)

6.19

6.23

6.42

6.32

5.58

Asset Turnover (?)

0.90

0.92

0.89

0.84

0.88

Market Valuation USD (mil)

P/E (TTM) (?)

7.31

.

Enterprise Value2 (?)

225.1

Price/Sales (TTM) (?)

0.49

.

Enterprise Value/Revenue (TTM) (?)

0.78

Price/Book (MRQ) (?)

0.95

.

Enterprise Value/EBITDA (TTM) (?)

4.33

Market Cap as of 23-Aug-20131 (?)

142.6

.

 

 

1-ExchangeRate: JPY to USD on 23-Aug-2013

98.510577

 

 

 

2-ExchangeRate: JPY to USD on 31-May-2013

100.886070

 

 

 

 

 

Annual Ratios

 

Financials in: USD (mil) 

Except for share items (millions) and per share items (actual units)         

 

 

31-May-2013

31-May-2012

31-May-2011

31-May-2010

31-May-2009

Financial Strength

Current Ratio (?)

1.36

1.16

1.17

1.14

1.06

Quick/Acid Test Ratio (?)

1.04

0.86

0.86

0.86

0.75

Working Capital1 (?)

48.6

25.0

24.7

17.4

6.7

Long Term Debt/Equity (?)

0.36

0.48

0.58

0.62

1.19

Total Debt/Equity (?)

0.85

1.00

1.13

1.21

1.93

Long Term Debt/Total Capital (?)

0.20

0.24

0.27

0.28

0.41

Total Debt/Total Capital (?)

0.46

0.50

0.53

0.55

0.66

Payout Ratio (?)

15.45%

19.34%

18.08%

14.96%

12.98%

Effective Tax Rate (?)

31.51%

43.41%

40.97%

40.66%

40.73%

Total Capital1 (?)

269.9

291.5

271.3

233.7

206.0

 

 

 

 

 

 

Efficiency

Asset Turnover (?)

0.90

0.92

0.89

0.84

0.88

Inventory Turnover (?)

6.19

6.23

6.42

6.32

5.58

Days In Inventory (?)

58.93

58.63

56.88

57.76

65.41

Receivables Turnover (?)

3.07

3.13

3.23

3.24

3.55

Days Receivables Outstanding (?)

118.95

116.71

112.89

112.78

102.96

Revenue/Employee2 (?)

-

613,877

560,470

460,469

447,369

Operating Income/Employee2 (?)

-

56,810

39,069

29,459

27,326

EBITDA/Employee2 (?)

-

108,157

85,615

69,128

63,591

 

 

 

 

 

 

Profitability

Gross Margin (?)

20.46%

20.85%

18.66%

16.29%

16.66%

Operating Margin (?)

9.48%

9.25%

6.97%

6.40%

6.11%

EBITDA Margin (?)

18.35%

17.62%

15.28%

15.01%

14.21%

EBIT Margin (?)

9.48%

9.25%

6.97%

6.40%

6.11%

Pretax Margin (?)

9.01%

9.04%

6.65%

5.59%

5.43%

Net Profit Margin (?)

6.17%

5.12%

3.93%

3.32%

3.22%

R&D Expense/Revenue (?)

-

3.82%

3.32%

2.35%

2.06%

COGS/Revenue (?)

79.54%

79.15%

81.34%

83.71%

83.34%

SG&A Expense/Revenue (?)

11.22%

6.91%

7.27%

7.18%

7.79%

 

 

 

 

 

 

Management Effectiveness

Return on Assets (?)

5.52%

4.71%

3.49%

2.78%

2.85%

Return on Equity (?)

13.60%

12.70%

9.90%

9.20%

12.80%

 

 

 

 

 

 

Valuation

Free Cash Flow/Share2 (?)

0.68

0.58

-0.33

1.12

-5.30

Operating Cash Flow/Share 2 (?)

2.55

4.73

3.89

2.66

1.49

1-ExchangeRate: JPY to USD Period End Date

100.88607

78.981276

81.24

91.035

95.455

2-ExchangeRate: JPY to USD Average for Period

100.88607

78.981276

81.24

91.035

95.455

 

Current Market Multiples

Market Cap/Earnings (TTM) (?)

7.31

Market Cap/Equity (MRQ) (?)

0.95

Market Cap/Revenue (TTM) (?)

0.49

Market Cap/EBIT (TTM) (?)

5.24

Market Cap/EBITDA (TTM) (?)

2.68

Enterprise Value/Earnings (TTM) (?)

11.82

Enterprise Value/Equity (MRQ) (?)

1.54

Enterprise Value/Revenue (TTM) (?)

0.78

Enterprise Value/EBIT (TTM) (?)

8.47

Enterprise Value/EBITDA (TTM) (?)

4.33


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.65.96

UK Pound

1

Rs.102.91

Euro

1

Rs.86.58

 

 

INFORMATION DETAILS

 

Report Prepared by :

SDA

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)